Skip to main content
. 2015 May 20;5:10223. doi: 10.1038/srep10223

Table 2. Comparison of baseline data (week 0) of Crohn’s disease patients who achieved one-year steroid-free remission at week 52 (responders) with secondary non-responders group.

Feature Responders Non-responders p
Number of patients (%) n=44/61 (72%) n=17/61 (28%)  
Age (years) [mean ± SD] 30 ± 8 37 ± 13 ns
Male/female –n (%) 22/22 7/10  
Disease duration (years) [mean ± SD] 5 ± 3 6 ± 5 ns
C-reactive protein (mg/l) [mean ± SD] 16.4 ± 15.7 35.3 ± 38.7 0.01
Erythrocyte sedimentation rate (mm/h) [mean ± SD] 30 ± 18 37 ± 23 ns
Red blood cell count (106/mm3) [mean ± SD] 4.4 ± 0.8 4.4 ± 0.7 ns
Hemoglobin (g/dl) [mean ± SD] 12.5 ± 2.1 11.6 ± 2.5 ns
Hematocrit (%) [mean ± SD] 38 ± 5 36 ± 6 ns
White blood cell count (103/mm3) [mean ± SD] 7.3 ± 3.5 7.9 ± 4.2 ns
Platelets (103/mm3) [mean ± SD] 328 ± 98 429 ± 103 0.009
Body mass index (kg/m2) [mean ± SD] 21.2 ± 3 20.9 ± 3.3 ns
Crohn’s Disease Activity Index [median (95%CI)] 264 (220  –  294) 304 (216  –  331) ns
Simple Endoscopic Score for CD (SES-CD) [median (95%CI)] 12 (11  –  18) 12 (4 – 25) ns
Ileal SES-CD [median (95%CI)] 6 (4  –  7) 6 (3  –  6) ns
Colonic SES-CD [median (95%CI)] 9 (6  –  12) 12 (11  –  18) ns
Disease location – n (%)      
L1 (ileal) 18/44 (41%) 9/17 (53%) ns
L3 (ileocolonic) 26/44 (59%) 8/17 (47%) ns
Disease behavior – n (%)      
B1 (inflammatory) 27/44 (61%) 5/17 (29%) 0.04
B2 (stricturing) 6/44 (14%) 4/17 (24%) ns
B3 (penetrating) 11/44 (25%) 8/17 (47%) ns
Previous surgery – n (%) 15/44 (34%) 9/17 (53%) ns
Medications      
Steroids 21/44 (48%) 5/17 (29%) ns
Azathioprine 39/44 (87%) 14/17 (82%) ns
Aminosalicylates 43/44 (98%) 17/17 (100%) ns
Probiotics 33/44 (75%) 13/17 (76%) ns
Antibiotics 8/44 (18%) 7/17 (41%) ns
Previous anti-TNF therapy 5/44 (11%) 3/17 (18%) ns

Data are presented as means with standard deviations (SD) or medians with 95% confidence intervals (CI).

HHS Vulnerability Disclosure